Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on biosimilar monoclonal antibodies market provides an in-depth analysis of segments and sub-segments in global as well as regional biosimilar monoclonal antibodies market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional biosimilar monoclonal antibodies market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global biosimilar monoclonal antibodies market. According to the report the global biosimilar monoclonal antibodies market is projected to grow at a CAGR of 55.2% over the forecast period of 2018-2024.
A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancer.
The global biosimilar monoclonal antibodies market is driven by factors such as rising demand for biosimilar drugs owing to their cost-effectiveness, patent expiration of biologics, and prevalence of chronic diseases among geriatric population. However, unfavorable government regulations in developed economies and high cost associated with the manufacturing process are likely to act as a primary restraining factor affecting the global biosimilar monoclonal antibodies market over the forecast period. Moreover, emerging markets owing to relaxed regulations are expected to provide more opportunities for the manufacturers of biosimilar drugs.
Among the geographies, North
America hold maximum share in the global biosimilar monoclonal antibodies market over the forecast period. The factors such as well-developed healthcare
infrastructures and favorable reimbursement scenario drive the growth of
market in the North America region. Furthermore, Europe is an important market
for biosimilar monoclonal antibodies market globally due to favorable
regulatory policies designed by the European medical association (EMA) and
since Europe was the first region to draft guidelines for approval of
biosimilar products. Moreover, Asia Pacific is expected to be the fastest-growing region in this market owing to the expanding patient population and new
product approvals in the japan region.
The report on global biosimilar monoclonal antibodies market covers segments such as application and drug class. On the basis of application, the global biosimilar monoclonal antibodies market is categorized into diagnostic applications, therapeutic applications, and protein purification. On the basis of drug class, the global biosimilar monoclonal antibodies market is categorized into rituximab, infliximab, abciximab, trastuzumab, adalimumab, and bevacizumab.
The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region.
The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-Pacific region offers substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global biosimilar monoclonal antibodies market such as Pfizer, Inc., Novartis AG, Reliance Life Sciences, Allergan plc, Coherus BioSciences, Inc., Biocon, Boehringer Ingelheim GmbH, BioXpress Therapeutics SA, Intas Pharmaceuticals Limited and Genor BioPharma Co. Ltd.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global biosimilar monoclonal antibodies market. Moreover, IGR-Growth matrix analysis given in the report brings insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of biosimilar monoclonal antibodies market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the biosimilar monoclonal antibodies market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the biosimilar monoclonal antibodies market to understand the present and future trends in this market and formulate their strategies accordingly.
Please Choose One of them.